© The Canadian Journal of Urology™; 19(Supplement 1); October 2012
23.
Zhanel GG, Hisanaga TL, Laing NM et al. Antibiotic resistance
in Eschericia coli outpatient urinary isolates: final results from
the North America Urinary Tract Infection Collaborative
Alliance (NAUTICA).
Int J Antimicrob Agents
2006;27(6):468-476.
24.
Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial
resistance among uropathogens that cause community-acquired
urinary tract infections in women: A nationwide analysis.
Clin
Infect Dis
2001;33(1):89-94.
25.
Karlowsky JA, Lagacé-Wiens PRS, Simmer PJ et al.Antimicrobial
resistance in urinary tract pathogens inCanada from2007 to 2009:
CANWARDsurveillance study.
AntimicrobAgents Chemother
2011;
55(7):3169-3175.
26.
Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ,
Stamm WE. Guidelines for antimicrobial treatment of
uncomplicated acute bacterial cystitis and acute pyelonephritis
in women.
Clin Infect Dis
1999;29(4):745-758.
27.
Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this
woman have an acute uncomplicated urinary tract infection?
JAMA
2002;287(20):2701-2710.
28.
McIsaac WJ, Mazzulli T, Moineddin R, Raboud J, Ross S.
Uropathogen resistance in adult women presenting to family
physicians with acute cystitis.
Can J Infect DisMedMicrobiol
2004;
15(5):266-270.
29.
McIsaac WJ, Mazzulli T, Permaul J, Moineddin R, Low DE.
Community-acquiredantibioticresistanceinurinaryisolatesfrom
adult women inCanada.
Can J Infect DisMedMicrobiol
2006;17(6):
337-340.
30.
BCCentre for Disease Control.Antimicrobial resistance trends in
the province of British Columbia, 2010. 2010AMR trend reports,
.
31.
PeiranoG, RichardsonD, Nigrin J et al. High prevalence of ST131
isolates producing CTX-M-15 and CTX-M-14 among extended
spectrum-beta-lactamase-producing Eschericia coli isolates
from Canada.
Antimicrob Agent Chemother
2010;54(3):1327-30.
32.
Pitout J. Infections with extended-spectrum [beta]-lactamase-
producing enterobacteriaceae: changing epidemiology and drug
treatment choices.
Drugs
2010;70(3):313-333.
33.
Nicolle LE. Update in adult urinary tract infection.
Curr Infect Dis
Rep
2011;13(6):552-560.
34.
Raz R, Chazzan B, Kennes Y et al. Empiric use of trimethoprim-
sulfamethoxazole (TMP-SMX) in the treatment of women with
uncomplicated urinary tract infections, in a geographical area
with a high prevalence of TMP-SMX-resistant uropathogens.
Clin Infect Dis
2002;34(9):1165-1169.
35.
Little P, Merriman R, Turner S et al. Presentation, pattern, and
natural course of severe symptoms, and role of antibiotics
and antibiotic resistance among patients presenting with
suspected uncomplicated urinary tract infection in primary care:
observational study.
BMJ
2010:340:
b5633doi:10.1136/bmj.b5633.
36.
McNultyCAM, Richards J, LivermoreDMet al. Clinical relevance
of laboratory-reportedantibiotic resistance inacuteuncomplicated
urinary tract infections inprimarycare.
JAntimicrobChemother
2006;
58(5):1000-1008.
37.
Kilgore KM, March KL, Guglielmo. Risk factors for community-
acquired ciprofloxacin-resistant Eschericia coli urinary tract
infection.
Ann Pharmacother
2004;38(7-8):1148-1152.
38.
Hillier S, Roberts Z, Dunstan F, Butler C, Howard A, Palmer S.
Prior antibiotics and risk of antibiotic-resistant community-
acquired urinary tract infection: a case-control study.
J Antimicrob
Chemother
2007;60(1):92-99.
39.
Colgan R, Johnson JR, Kuskowski M, Gupta K. Risk factors for
trimethorprim-sulfamethoxazole resistance in patients with
acuteuncomplicatedcystitis.
AntimicrobAgentChemother
2008;52(3):
846-851.
40.
Sandberg T, Skoog G, Hermansson AB et al. Ciprofloxacin for
7
days versus 14 days in women with acute pyelonephritis: a
randomized, open-label and double-blind, placebo controlled,
non-inferiority trial.
Lancet
2012;380(9840):484-90.
41.
Pallett J, HandKJ. Complicated urinary tract infections: practical
solutions for the treatment of multiresistant Gram-negative
bacteria.
J Antimicrob Chemother
2010;65(
Suppl 3):iii25–33
42.
Nicolle L. AMMI Canada Guidelines Committee: Complicated
urinarytractinfectioninadults.
CanJInfectDisMedMicrobiol
2005;
16(6):349-360.
43.
Stapleton A, Latham RH, Johnson C, Stamm WE. Postcoital
antimicrobial prophylaxis for recurrent urinary tract infection: a
randomized, double-blind, placebo-controlled trial.
JAMA
1990;
264(6):703-706.
44.
Nicolle LE. Uncomplicated urinary tract infection in adults
includinguncomplicatedpyelonephritis.
UrolClinNorthAm
2008;
35(1):1-12.
45.
Wang C-H, Fang C-C, Chen N-C et al. Cranberry-containing
products for thepreventionof urinary tract infections in susceptible
populations: a systematic reviewandmeta-analysis of randomized
controlled trials.
Arch Intern Med
2012;172(13):988-996.
Mazzulli
48
